Rebecca Miksad, MD
Clinical Instructor
Boston University School of Medicine
Dept of Hematology & Oncology





Rebecca Miksad is a medical oncologist and health outcomes researcher who serves as senior medical director at Flatiron Health. In this role, Rebecca focuses on generating real-world evidence, establishing regulatory-grade quality standards and contributing to the development of clinically-relevant methods to real-world data evaluation and analyses.

Rebecca maintains a clinical practice at Boston Medical Center. A nationally recognized clinician and researcher, Rebecca regularly publishes in leading medical journals, serves on national committees and lectures internationally.

Prior to joining Flatiron Health, Rebecca was an assistant professor at Harvard Medical School, senior scientist at the Institute for Technology Assessment at Massachusetts General Hospital, and director of gastrointestinal oncology and gastrointestinal oncology clinical trials at Beth Israel Deaconess Medical Center (BIDMC). Rebecca’s academic research focused on improving cancer treatment decision-making through better characterization of patient outcomes and increasing relevance of clinical trial endpoints. Rebecca earned a BA cum laude in economics from Harvard University and an MD with honors in research from Cornell University. She was a resident in internal medicine at Cornell University/New York-Presbyterian Hospital, and completed hematology and medical oncology fellowships at Harvard Medical School/BIDMC. Rebecca earned a MMS from Harvard Medical School and an MPH in Clinical Effectiveness from the Harvard School of Public Health in clinical effectiveness (with an emphasis on decision science). She also completed a post-doctoral fellowship in the Dana-Farber/Harvard Cancer Center Program in Cancer Outcomes Research Training (PCORT).
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

  1. O'Neill T, Miksad R, Miller D, Maloney L, John A, Hiller C, Hornberger J. ISPOR, the FDA, and the Evolving Regulatory Science of Medical Device Products. Value Health. 2019 Jul; 22(7):754-761. PMID: 31277820.
     
  2. Griffith SD, Tucker M, Bowser B, Calkins G, Chang CJ, Guardino E, Khozin S, Kraut J, You P, Schrag D, Miksad RA. Generating Real-World Tumor Burden Endpoints from Electronic Health Record Data: Comparison of RECIST, Radiology-Anchored, and Clinician-Anchored Approaches for Abstracting Real-World Progression in Non-Small Cell Lung Cancer. Adv Ther. 2019 May 28. PMID: 31140124.
     
  3. Miksad RA, Samant MK, Sarkar S, Abernethy AP. Small But Mighty: The Use of Real-World Evidence to Inform Precision Medicine. Clin Pharmacol Ther. 2019 Jul; 106(1):87-90. PMID: 31112289.
     
  4. Ng K, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Miksad R, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin BM, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Ganser C, Wilkinson B, Mackintosh C, Zheng H, Hollis BW, Meyerhardt JA, Fuchs CS. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Progression-Free Survival Among Patients With Advanced or Metastatic Colorectal Cancer: The SUNSHINE Randomized Clinical Trial. JAMA. 2019 04 09; 321(14):1370-1379. PMID: 30964527.
     
  5. Khozin S, Carson KR, Zhi J, Tucker M, Lee SE, Light DE, Curtis MD, Bralic M, Kaganman I, Gossai A, Hofmeister P, Torres AZ, Miksad RA, Blumenthal GM, Pazdur R, Abernethy AP. Real-World Outcomes of Patients with Metastatic Non-Small Cell Lung Cancer Treated with Programmed Cell Death Protein 1 Inhibitors in the Year Following U.S. Regulatory Approval. Oncologist. 2019 May; 24(5):648-656. PMID: 30591549.
     
  6. Abou-Alfa GK, Miksad RA, Tejani MA, Williamson S, Gutierrez ME, Olowokure OO, Sharma MR, El Dika I, Sherman ML, Pandya SS. A Phase Ib, Open-Label Study of Dalantercept, an Activin Receptor-Like Kinase 1 Ligand Trap, plus Sorafenib in Advanced Hepatocellular Carcinoma. Oncologist. 2019 Feb; 24(2):161-e70. PMID: 30352941.
     
  7. Goyal L, Zheng H, Abrams TA, Miksad R, Bullock AJ, Allen JN, Yurgelun MB, Clark JW, Kambadakone A, Muzikansky A, Knowles M, Galway A, Afflitto AJ, Dinicola CF, Regan E, Hato T, Mamessier E, Shigeta K, Jain RK, Duda DG, Zhu AX. A Phase II and Biomarker Study of Sorafenib Combined with Modified FOLFOX in Patients with Advanced Hepatocellular Carcinoma. Clin Cancer Res. 2019 Jan 01; 25(1):80-89. PMID: 30190369.
     
  8. Liu PH, Huo TI, Miksad RA. Hepatocellular Carcinoma with Portal Vein Tumor Involvement: Best Management Strategies. Semin Liver Dis. 2018 08; 38(3):242-251. PMID: 30041276.
     
  9. Brunt E, Aishima S, Clavien PA, Fowler K, Goodman Z, Gores G, Gouw A, Kagen A, Klimstra D, Komuta M, Kondo F, Miksad R, Nakano M, Nakanuma Y, Ng I, Paradis V, Nyun Park Y, Quaglia A, Roncalli M, Roskams T, Sakamoto M, Saxena R, Sempoux C, Sirlin C, Stueck A, Thung S, Tsui WMS, Wang XW, Wee A, Yano H, Yeh M, Zen Y, Zucman-Rossi J, Theise N. cHCC-CCA: Consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology. 2018 07; 68(1):113-126. PMID: 29360137.
     
  10. Qian ZR, Rubinson DA, Nowak JA, Morales-Oyarvide V, Dunne RF, Kozak MM, Welch MW, Brais LK, Da Silva A, Li T, Li W, Masuda A, Yang J, Shi Y, Gu M, Masugi Y, Bui J, Zellers CL, Yuan C, Babic A, Khalaf N, Aguirre A, Ng K, Miksad RA, Bullock AJ, Chang DT, Tseng JF, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar M, Wollison B, Laing A, Hahn WC, Meyerson M, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Wolpin BM. Association of Alterations in Main Driver Genes With Outcomes of Patients With Resected Pancreatic Ductal Adenocarcinoma. JAMA Oncol. 2018 Mar 08; 4(3):e173420.View Related Profiles. PMID: 29098284.
     
Showing 10 of 57 results. Show More

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 57 publications over 16 distinct years, with a maximum of 9 publications in 2016

YearPublications
20021
20051
20062
20072
20083
20095
20104
20116
20121
20131
20143
20151
20169
20177
20187
20194
Contact for Mentoring:

820 Harrison Avenue
Boston MA 02118
Google Map


Miksad's Networks
Click the "See All" links for more information and interactive visualizations
Concepts
_
Co-Authors
_
Similar People
_
Same Department